Abstract

Objective.:To report the high incidence of barotrauma in critically ill patients admitted to the intensive care unit (ICU) with coronavirus disease 2019 (COVID-19) and to discuss its implications.Design.:Retrospective cohort study.Setting.:ICU of an academic county hospital in Los Angeles, CA admitted from March 15-June 20, 2020.Patients.:77 patients with COVID-19 pneumonia. 75 patients met inclusion criteria.Results.:21% of patients with severe COVID-19 sustained barotrauma (33% of patients receiving IMV, 8% of patients receiving (NIV). There were no differences between the barotrauma and non-barotrauma groups regarding demographics, illness severity, or medications received, nor tidal volume or average/peak airway pressures in those receiving IMV. In the barotrauma group there was a greater proportion of patients receiving therapeutic anticoagulation (81% vs. 47%, p = 0.023) and ventilated using airway pressure release ventilation mode (13% vs. 0%, p = 0.043). Barotrauma was associated with increased likelihood of receiving a tracheostomy (OR 2.58 [0.23-4.9], p = 0.018]), longer median ICU length of stay (17 days vs. 7 days, p = 0.03), and longer median length of hospitalization (26 days vs. 14 days, p < 0.001). There was also a trend toward prolonged median duration of IMV (12.5 days vs 7 days, p = 0.13) and higher average mortality (56% vs 37%, p = 0.25).Conclusions.:Barotrauma is seen in 5-12% of patients with ARDS receiving IMV and is exceedingly rare in patients receiving NIV. We report a high incidence of barotrauma observed in critically ill patients with COVID-19 requiring either NIV or IMV. While there was a trend toward increased mortality in patients with barotrauma, this did not reach statistical significance. The increased incidence of barotrauma with COVID-19 may be a product of the pathophysiology of this disease state and a heightened inflammatory response causing rampant acute lung injury. Evidence-based medicine and lung-protective ventilation should remain the mainstay of treatment.

Highlights

  • The search for effective treatments for coronavirus disease 2019 (COVID-19) has become a priority in the medical community since the pandemic began

  • Barotrauma was seen in 30% of patients receiving invasive mechanical ventilation (IMV) diagnosed with Middle East Respiratory Syndrome coronavirus (MERS-CoV), 44% of patients treated for influenza A H7N9 (H7N9), and 8% of patients treated for influenza A H1N1 (H1N1).[20,21]. In this single center study, we examine a large sample of critically ill patients in order to better characterize the incidence of barotrauma in patients with COVID-19 respiratory failure, identify the risk factors associated with barotrauma, and determine its impact on patient mortality and length of hospital stay

  • Between March 15 and June 20 of 2020, 77 patients were admitted to the intensive care unit (ICU) with COVID-19, 75 of whom met Incidence of Barotrauma Sustained in CriƟcally Ill COVID-19 PaƟents

Read more

Summary

Introduction

The search for effective treatments for coronavirus disease 2019 (COVID-19) has become a priority in the medical community since the pandemic began. Invasive mechanical ventilation (IMV) continues to be a mainstay of treatment for severe respiratory failure. Despite novel therapies and lung-protective ventilation, mortality remains high for patients requiring IMV, often due to complications from sedation, nosocomial infections, and barotrauma.[1,2,3] The high mortality associated with each of these risks makes understanding the sequelae of severe COVID-19 in the critical care setting all the more important.[4,5,6]. Barotrauma, defined as the presence of air outside the pleural surface of the lung, is a known complication of the acute respiratory distress syndrome (ARDS), occurring in 8-11% of all cases.[6,7,8,9,10,11] Since the development of the ARDSnet protocol, low tidal volume ventilation at 6-8cc/kg based on ideal body weight (IBW) has reduced these rates to 5-8%.8-11

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call